Treating and preventing motor neuron diseases using nicotinamide riboside
Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.
1. A method of treating or preventing amyotrophic lateral sclerosis (ALS) in a subject comprising administering to the subject a composition comprising pterostilbene and a compound of Formula I:
wherein, independently for each occurrence:
R 1 , and R 3 are selected from hydrogen, halogen, —CN, —NO 2 , —OR 14 , —N(R 14 ) m , —R 13 , substituted or unsubstituted (C 1 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
R 4 and R 5 are selected from hydrogen, halogen, —CN, —NO 2 , —OR 14 , —N(R 14 ) m , substituted or unsubstituted (C 1 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
R 6 , R 8 , R 11 , and R 12 are selected from hydrogen, (C 1 -C 6 )alkyl, —((C 1 -C 6 )alkylene)N(R 14 ) m , —C(O)((C 1 -C 6 )alkylene)N(R 14 ) m , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 14 , and —N(R 14 ) m ;
R 7 , R 9 , and R 10 are selected from —((C 1 -C 6 )alkylene)N(R 14 ) m , —OR 14 , and —N(R 14 ) m ;
R 13 is selected from —OR 14 , —N(R 14 ) m , —C(O)(R 14 ), —C(O)(OR 14 ), —C(O)N(R 14 ) m , —S(O) 2 (OR 14 ), —S(O)OR 14 , and —S(O) 2 N(R 14 ) m ;
R 14 is selected from hydrogen, (C 1 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; and
X is O, S, or N(R 14 );
m is 2 or 3;
provided that at least one of R 1 , R 2 , and R 3 is R 13 .
2. The method of claim 1 , wherein the compound of Formula I is nicotinamide riboside.
3. A method of slowing or reversing the progression of amyotrophic lateral sclerosis (ALS) in a subject comprising administering to the subject a composition comprising pterostilbene and a compound of Formula I:
wherein, independently for each occurrence:
R 1 , and R 3 are selected from hydrogen, halogen, —CN, —NO 2 , —OR 14 , —N(R 14 ) m , —R 13 , substituted or unsubstituted (C 1 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
R 4 and R 5 are selected from hydrogen, halogen, —CN, —NO 2 , —OR 14 , —N(R 14 ) m , substituted or unsubstituted (C 1 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl;
R 6 , R 8 , R 11 , and R 12 are selected from hydrogen, (C 1 -C 6 )alkyl, —((C 1 -C 6 )alkylene)N(R 14 ) m , —C(O)((C 1 -C 6 )alkylene)N(R 14 ) m , cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —OR 14 , and —N(R 14 ) m ;
R 7 , R 9 , and R 10 are selected from —((C 1 -C 6 )alkylene)N(R 14 ) m , —OR 14 , and —N(R 14 ) m ;
R 13 is selected from —OR 14 , —N(R 14 ) m , —C(O)(R 14 ), —C(O)(OR 14 ), —C(O)N(R 14 ) m , —S(O) 2 (OR 14 ), —S(O)OR 14 , and —S(O) 2 N(R 14 ) m ;
R 14 is selected from hydrogen, (C 1 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; and
X is O, S, or N(R 14 );
m is 2 or 3;
provided that at least one of R 1 , R 2 , and R 3 is R 13 .
4. The method of claim 3 , wherein the compound of Formula I is nicotinamide riboside.
5. The method of claim 1 , wherein the method further comprising administering a fatty acid supplement to the subject.
6. The method of claim 5 , wherein the fatty acid supplement is coconut oil.
7. The method of claim 1 , wherein the administration of the composition comprises administering one or more doses of the composition.
8. The method of claim 7 , wherein each dose of the composition comprises at least 40 mg of pterostilbene.
9. The method of claim 7 , wherein each dose of the composition comprises at least 200 mg of nicotinamide riboside.
10. The method of claim 7 , wherein ten or more doses of the composition are administered.
11. The method of claim 7 , wherein the dose of the composition is administered at least once a week.
12. The method of claim 7 , wherein the doses are administered for at least 7 days.
13. The method of claim 1 , wherein the composition is administered orally.
14. The method of claim 1 , wherein the method further comprises administering a motor function test.
15. The method of claim 14 , wherein the motor function test is Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).
16. The method of claim 1 , wherein the method further comprises administering a cognition and conduct function test selected from Complutense Verbal Learning Test (TAVEC), Symbol Digit Modalities Test (SDMT), Verbal Fluency Test, Digit Span (Wechsler Memory Scale III), D2 Attention Test, Wechsler Memory Scale III for Letters and Numbers, London Tower Test, Stroop test, Frontal System Behavior Scale (FrSBe), or Brief Test (subjective conduct).
17. The method of claim 1 , wherein the method further comprises measuring a feature in the subject.
18. The method of claim 17 , wherein the feature is associate with inflammation.
19. The method of claim 18 , wherein the feature is the level of a cytokine, level of amyloid A protein, level of macrophage activation marker neopterin, level of creatine phosphokinase (CPK), level of erythrocyte sedimentation rate, level of C-reactive protein, plasma viscosity, or cell count.
20. The method of claim 19 , wherein the cytokine is TNFa, IFNy, IL-1, IL-6, IL-8, or TGFβ.